VPC
TARS icon

Vestal Point Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Vestal Point Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.1M Buy
1,050,000
+850,000
+425% +$54.3M 1.54% 23
2026
Q1 		$14M Buy
+200,000
New +$14M 0.39% 61
2024
Q4 		– Sell
-230,000
Closed -$7.56M – 90
2024
Q3 		$7.56M Buy
+230,000
New +$6.46M 0.57% 41

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vestal Point Capital's TARS Position: Q2 2026 in Review

Vestal Point Capital increased its Tarsus Pharmaceuticals (TARS) stake by 425% in Q2 2026, buying an estimated $54.3M and bringing the position to 1,050,000 shares worth $66.1M. The position accounts for 1.54% of the portfolio, ranked #23.

Vestal Point Capital first reported a position in TARS in Q3 2024 and has held it in 3 quarters since. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Vestal Point Capital held 1,050,000 shares of Tarsus Pharmaceuticals worth $66.1M as of Q2 2026.
  • Vestal Point Capital bought 850,000 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $54.3M.
  • Tarsus Pharmaceuticals made up 1.54% of Vestal Point Capital's portfolio in Q2 2026, its #23 holding.
  • Vestal Point Capital first reported a position in Tarsus Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.